Zhongchao Inc. (ZCMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZCMD Stock Summary
- With a one year PEG ratio of 0.45, ZHONGCHAO INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.03% of US stocks.
- Price to trailing twelve month operating cash flow for ZCMD is currently 66.12, higher than 93.94% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of 589.66%, ZHONGCHAO INC's debt growth rate surpasses 97.05% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to ZHONGCHAO INC are TGEN, UTMD, WNW, ALPP, and MITQ.
- Visit ZCMD's SEC page to see the company's official filings. To visit the company's web site, go to www.izcmd.com.
ZCMD Valuation Summary
- In comparison to the median Technology stock, ZCMD's price/earnings ratio is 282.33% lower, now standing at -42.3.
- Over the past 37 months, ZCMD's price/earnings ratio has gone down 75.6.
Below are key valuation metrics over time for ZCMD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZCMD | 2023-03-14 | 1.9 | 0.9 | -42.3 | -24.1 |
| ZCMD | 2023-03-13 | 1.9 | 0.8 | -42.0 | -23.8 |
| ZCMD | 2023-03-10 | 1.8 | 0.8 | -41.3 | -23.2 |
| ZCMD | 2023-03-09 | 1.9 | 0.8 | -42.2 | -23.9 |
| ZCMD | 2023-03-08 | 1.9 | 0.8 | -41.9 | -23.7 |
| ZCMD | 2023-03-07 | 1.8 | 0.8 | -41.3 | -23.2 |
ZCMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZCMD has a Quality Grade of C, ranking ahead of 45.59% of graded US stocks.
- ZCMD's asset turnover comes in at 0.685 -- ranking 24th of 51 Personal Services stocks.
- 500 - Internal server error
The table below shows ZCMD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.685 | 0.660 | 0.409 |
| 2020-12-31 | 0.685 | 0.660 | 0.409 |
| 2019-12-31 | 0.937 | 0.687 | 0.772 |
ZCMD Stock Price Chart Interactive Chart >
ZCMD Price/Volume Stats
| Current price | $1.11 | 52-week high | $1.60 |
| Prev. close | $1.15 | 52-week low | $0.60 |
| Day low | $1.09 | Volume | 1,600 |
| Day high | $1.15 | Avg. volume | 60,853 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $1.18 | Market Cap | 20.07M |
Zhongchao Inc. (ZCMD) Company Bio
Zhongchao, Inc. is a holding company that engages in the provision of healthcare information, education, and training services. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting primarily of clinical practice training, open classes of medical topics, interactive case studies, academic conference & workshops, continuing education courses, articles & short videos with educational healthcare content to healthcare professionals as well as the public. The company was founded by Wei Guang Yang on April 16, 2019 and is headquartered in Shanghai, China.
Latest ZCMD News From Around the Web
Below are the latest news stories about ZHONGCHAO INC that investors may wish to consider to help them evaluate ZCMD as an investment opportunity.
Zhongchao Inc. Releases Survey Results for Bone Marrow Cancer Patient Services with More than 80% Patients Indicating Full SatisfactionZhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the survey results of bone marrow patient services provided by Zhongxin Health, a platform of Shanghai Zhongxin Medical Technology Co., Ltd., one of the companies that Zhongchao consolidates the financial and operations results with through a certain contractual arrangements. The survey revealed that appro |
Zhongchao Inc. Renews Partnership with Johnson & Johnson (China)Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the renewal of the partnership between Zhongchao Medical Technology (Shanghai) Co., Ltd. ("Zhongchao Shanghai"), of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements and Johnson & Johnson (China) Investment Limited ("J&J"). The renewed partnershi |
Zhongchao Inc. Announces the Application of ChatGPT for Its MDMOOC Platform to Assist Physicians in Clinic Decision Making and Improve Treatment EfficiencyZhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that its MDMOOC Platform will apply the ChatGPT (Chat Generative Pre-trained Transformer) to provide assistance for physicians in clinical decision-making to improve the efficiency of diagnosis and treatment. This is an expanded application of ChatGPT by Zhongchao since its initial application of ChatGPT t |
Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and ExperienceZhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content thr |
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to ChinaZhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical"), one of the China operating entities, of which the Company consolidates the financial results with through certain contractual arrangements, obtained the general distribution rights in Mainland China for anti-influenza drug f |
ZCMD Price Returns
| 1-mo | -2.74% |
| 3-mo | -11.90% |
| 6-mo | 2.78% |
| 1-year | -11.20% |
| 3-year | -46.89% |
| 5-year | N/A |
| YTD | -3.36% |
| 2022 | -35.47% |
| 2021 | 4.71% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...